Namitecan: a Hydrophilic Camptothecin with a Promising Preclinical Profile

Author(s): G. L. Beretta, V. Zuco, M. De Cesare, P. Perego, N. Zaffaroni

Journal Name: Current Medicinal Chemistry

Volume 19 , Issue 21 , 2012

Become EABM
Become Reviewer

Abstract:

Camptothecins are still among the most widely prescribed and effective anticancer drugs. Unfortunately, important drawbacks including water insolubility, lactone instability, reversibility of the drug–target interaction, drug resistance and toxicity are responsible for treatment failure and often require suspension of the drug administration itself. In order to overcome such drawbacks, several options in chemical manipulation of natural camptothecin have been explored, and effective compounds have been identified in a novel series of 7- oxyiminomethyl derivatives. Among the compounds of this series, the hydrophilic derivative namitecan (7 (2-aminoethoxy) iminomethyl camptothecin) has been selected for further development. The relevant features of namitecan are: 1) marked cytotoxic potency - likely related to multiple factors, including i) a potent inhibition of topoisomerase I, ii) a persistent stabilization of the cleavable complex, iii) an increased intracellular accumulation, and iv) a peculiar subcellular localization; 2) enhanced lactone stability and favorable pharmacokinetics; 3) remarkable antitumor efficacy in a large panel of human tumor xenografts (including tumor models relatively resistant to topotecan and irinotecan), particularly on squamous cell carcinomas. The clinical development of namitecan is currently ongoing. Namitecan exhibited an acceptable toxicity profile, with neutropenia being the dose-limiting toxic effect, and clinical benefit was appreciable in patients with different tumor types, particularly bladder and endometrium carcinomas. In this article, we review the relevant features of namitecan, with particular reference to its advantages compared with the two analogues (topotecan and irinotecan) approved for clinical use.

Keywords: Antitumor therapy, Camptothecins, Cellular pharmacology, Clinical studies, Drug resistance, Gimatecan, Namitecan, 7- oxyiminomethyl derivatives, Topoisomerase I, Tumor cells

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 21
Year: 2012
Published on: 21 June, 2012
Page: [3488 - 3501]
Pages: 14
DOI: 10.2174/092986712801323252
Price: $65

Article Metrics

PDF: 17